United States Continuous Glucose Monitoring - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The continuous glucose monitoring market size in 2026 is estimated at USD 7.43 billion, growing from 2025 value of USD 6.28 billion with 2031 projections showing USD 17.16 billion, growing at 18.23% CAGR over 2026-2031. This report is Segmented by Component (Sensors, Transmitters, Receivers), End User (Hospitals/Clinics, Home/Personal Use), Demography (Adult, Pediatric), and Geography (United States). The Market Forecasts are Provided in Terms of Value (USD).

United States Continuous Glucose Monitoring Market Trends and Insights

Rising Diabetes Prevalence and Earlier Diagnoses

CDC surveillance shows adult diabetes prevalence rising from 9.7% in 1999-2000 to 15.8% in 2021-2023, translating to 38.4 million Americans who potentially benefit from continuous glucose monitoring market solutions. Younger adults are being screened sooner, which pushes CGM adoption earlier in the disease course. Payers increasingly view CGM as a frontline therapy that prevents severe hypoglycemia and costly hospitalizations, making reimbursement justification easier. Providers treat CGM as a foundational self-management tool rather than an advanced add-on, a perception shift that enlarges the addressable base. As a result, the continuous glucose monitoring market gains sustained volume tailwinds from both Type-1 and Type-2 cohorts, whose treatment plans now anchor around real-time data feedback.

Medicare/Medicaid Expansion for Type-2 Basal-Only Patients

In April 2023, CMS broadened coverage to include Type-2 patients using basal insulin only, opening CGM eligibility to an extra 1.5 million beneficiaries. Adoption momentum varies by state Medicaid policy, yet progressive states already report higher authorization rates that speed volume uptake. The policy decision rests on evidence that CGM reduces emergency visits and inpatient costs, benefits that resonate with value-based care contracts. Pharmacy benefit pathways continue to evolve, so manufacturers are expanding distribution channels and patient support programs to navigate differing durable-equipment billing rules. The net effect is a medium-term surge in unit sales as both public and commercial payers harmonize benefit designs.

GLP-1 Induced Glucose Normalization Reduces CGM Starts

Rapid uptake of GLP-1 receptor agonists such as semaglutide brings many patients to normalized HbA1c levels, lowering perceived need for continuous monitoring. Studies show approximately 46% of non-diabetic users discontinue GLP-1 within a year, causing unpredictable sensor demand. Early discontinuation produces gaps in monitoring continuity, making it difficult for providers to justify CGM prescriptions. Nonetheless, emerging evidence supports CGM use during dose titration and to catch hypoglycemia in aggressively treated cohorts. Manufacturers now educate clinicians on complementary roles for CGM even when pharmacotherapy remains effective, which may soften this negative impact over time.

Other drivers and restraints analyzed in the detailed report include:

• Sensor Price Erosion Below USD 60 per 14-Day Wear Period
• Shift to OTC Wellness CGMs Expands Addressable Base
• Patch-Pump and CGM Bundles Limit Stand-Alone Sensor Sales

Segment Analysis

Sensors captured 87.32% of the continuous glucose monitoring market in 2025 and are forecast to compound at an 18.05% rate through 2031. This dominance stems from 14- to 15-day replacement cycles that create subscription-like revenue predictability. The continuous glucose monitoring market size for sensor hardware is on track to surpass USD 14.2 billion by 2031, underpinned by mass-production cost advantages and AI-ready data output. Dexcom’s G7 15-day sensor, cleared in April 2025, sustains 8.0% MARD accuracy, demonstrating how incremental performance gains support premium price points. Longer wear times and Bluetooth direct-to-phone links minimize the role of dedicated receivers, paving the way for consumer-scale adoption well beyond diabetes.

Durable components - receivers and transmitters - hold 12.68% share and grow at just 19.35% through the forecast. Their decelerating curve reflects smartphone ubiquity that makes proprietary displays obsolete. Transmitters lasting 90-180 days dampen replacement frequency, and regulatory scrutiny pushes manufacturers to extend life cycles further. Higher per-unit prices cushion revenue, yet overall share slips as sensors absorb much of the system’s value. Competitive focus, therefore, centers on transmitter miniaturization and waterproofing to simplify closed-loop pump pairing.

Complete Report Scope:

• By Component
  • Sensors
  • Transmitters
  • Receivers
• By End User
  • Hospitals/Clinics
  • Home/Personal Use
• By Demography
  • Adult
  • Pediatric

List of Companies Covered in this Report:

• Abbott Laboratories
• Medtronic
• Dexcom
• Senseonics
• Roche
• A. Menarini Diagnostics S.r.l.
• I-Sens
• Medtrum Technologies Inc.
• Nemaura Medical Inc.
• Zhejiang POCTech Co.,Ltd.
• MicroTech Medical

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support